New York: Karyopharm Therapeutics (NASDAQ:KPTI) Stock Has Just Had Its Buy Rating Reiterated by Jefferies. Shares now Have a $19.0 Target

September 17, 2017 - By Clifton Ray

 New York: Karyopharm Therapeutics (NASDAQ:KPTI) Stock Has Just Had Its Buy Rating Reiterated by Jefferies. Shares now Have a $19.0 Target

Investors sentiment increased to 2.4 in Q4 2016. Its up 0.88, from 1.52 in 2016Q3. It improved, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.

Mutual Of America Management has invested 0.02% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). The Massachusetts-based State Street has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Voya Inv Mngmt Limited Liability has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 82,752 were reported by Schwab Charles Management. Tcw Gru Incorporated holds 40,648 shares. Secor Capital Lp holds 66,484 shares. Tower Rech Cap Ltd Liability (Trc) invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Citadel Advsrs Lc invested 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Alliancebernstein Limited Partnership accumulated 34,930 shares. United Service Automobile Association has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 38,492 are owned by Susquehanna Int Gru Llp. First Personal Financial Svcs stated it has 1,187 shares. 51,080 are held by Piermont Cap Inc. Royal Comml Bank Of Canada accumulated 0% or 1,790 shares. Meeder Asset Mngmt holds 0% or 1,366 shares.

Karyopharm Therapeutics (NASDAQ:KPTI) Rating Reaffirmed

In analysts report issued on Monday, 11 September, The Buy rating of Karyopharm Therapeutics (NASDAQ:KPTI) shares was maintained at Jefferies, who now has a $19.0 TP on the stock. Jefferies’s TP suggests a possible upside of 72.73 % from the last stock close of the company.

Investors sentiment increased to 2.4 in Q4 2016. Its up 0.88, from 1.52 in 2016Q3. It improved, as 5 investors sold Karyopharm Therapeutics Inc shares while 15 reduced holdings. 14 funds opened positions while 34 raised stakes. 24.99 million shares or 9.31% more from 22.86 million shares in 2016Q3 were reported.

Mutual Of America Management has invested 0.02% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). The Massachusetts-based State Street has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Voya Inv Mngmt Limited Liability has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 82,752 were reported by Schwab Charles Management. Tcw Gru Incorporated holds 40,648 shares. Secor Capital Lp holds 66,484 shares. Tower Rech Cap Ltd Liability (Trc) invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Citadel Advsrs Lc invested 0% of its portfolio in Karyopharm Therapeutics Inc (NASDAQ:KPTI). Alliancebernstein Limited Partnership accumulated 34,930 shares. United Service Automobile Association has invested 0% in Karyopharm Therapeutics Inc (NASDAQ:KPTI). 38,492 are owned by Susquehanna Int Gru Llp. First Personal Financial Svcs stated it has 1,187 shares. 51,080 are held by Piermont Cap Inc. Royal Comml Bank Of Canada accumulated 0% or 1,790 shares. Meeder Asset Mngmt holds 0% or 1,366 shares.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Ratings Coverage

Among 13 analysts covering Karyopharm Therapeutics Inc. (NASDAQ:KPTI), 12 have Buy rating, 1 Sell and 0 Hold. Therefore 92% are positive. Karyopharm Therapeutics Inc. has $42 highest and $10 lowest target. $23.64’s average target is 114.91% above currents $11 stock price. Karyopharm Therapeutics Inc. had 22 analyst reports since August 11, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Tuesday, December 22 by Canaccord Genuity. Leerink Swann maintained Karyopharm Therapeutics Inc (NASDAQ:KPTI) on Tuesday, August 11 with “Outperform” rating. On Wednesday, September 9 the stock rating was initiated by Jefferies with “Buy”. The firm has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The firm has “Underperform” rating by Bank of America given on Tuesday, March 15. Canaccord Genuity maintained it with “Buy” rating and $1800 target in Tuesday, August 8 report. As per Monday, March 14, the company rating was maintained by JP Morgan. The stock of Karyopharm Therapeutics Inc (NASDAQ:KPTI) has “Outperform” rating given on Tuesday, June 28 by Robert W. Baird. The company was downgraded on Wednesday, January 6 by Jefferies. The rating was maintained by Cantor Fitzgerald on Friday, June 23 with “Buy”.

The stock increased 4.07% or $0.43 on September 15, reaching $11. About 432,710 shares traded or 146.40% up from the average. Karyopharm Therapeutics Inc (NASDAQ:KPTI) has risen 21.19% since September 17, 2016 and is uptrending. It has outperformed by 4.49% the S&P500.

Investors wait Karyopharm Therapeutics Inc (NASDAQ:KPTI) to report on November, 6. its quarterly earnings Wall Street analysts expect $-0.64 earnings per share, up $0.05 or 7.25 % from last year’s $-0.69 same quarter earnings. Karyopharm Therapeutics Inc’s Wall Street analysts see 0.00 % EPS growth, taking into account the $-0.64 EPS reproted in the previous quarter,

Karyopharm Therapeutics Inc. is a clinical-stage pharmaceutical company. The company has market cap of $518.53 million. The Firm is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It currently has negative earnings. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export compounds that inhibit the nuclear export protein, XPO1.

More notable recent Karyopharm Therapeutics Inc (NASDAQ:KPTI) news were published by: Streetinsider.com which released: “Karyopharm Therapeutics (KPTI) Presents Selinexor and KPT-9274 Clinical Data …” on September 08, 2017, also Seekingalpha.com with their article: “Karyopharm Therapeutics’ (KPTI) CEO Michael Kauffman on Q2 2017 Results …” published on August 08, 2017, Fool.com published: “Why Karyopharm Therapeutics Inc Stock Gained 16.4% in March” on April 07, 2017. More interesting news about Karyopharm Therapeutics Inc (NASDAQ:KPTI) were released by: Globenewswire.com and their article: “US FDA Division of Hematology Products Lifts Partial Clinical Hold on …” published on March 30, 2017 as well as Streetinsider.com‘s news article titled: “Karyopharm Therapeutics (KPTI) Names Michael Falvey as Chief Financial Officer” with publication date: September 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.